Glaucoma, a leading cause of global visual loss, affects approximately 80 million individuals worldwide [1]. The disease involves progressive damage to the optic nerve head, primarily attributed to high intraocular pressure (IOP) [2,3]. The most prevalent form, primary open-angle glaucoma (POAG), affects around 70 million people, while steroid-induced glaucoma (SIG) arises from long-term glucocorticoid use … Leggi tutto Advancements in Gene Therapy for Glaucoma: Targeting the Actin Cytoskeleton and Oxidative Stress